Abstract
Recent advancements in cancer treatment have introduced the use of aminocyanine molecules, activated by near-infrared (NIR) light, to induce vibrational responses that can selectively destroy cancer cells. This commentary critically examines a study that reports a 99% efficacy of this method against human melanoma cells in vitro, and significant tumor reduction in murine models. While the findings are promising, our analysis highlights crucial oversights in the study's implications for clinical applications. Specifically, the persistence of even a small fraction of cancer cells post-treatment poses significant risks for tumor regrowth and acquired resistance. Additionally, the study's approach neglects the heterogeneity of cancer cells and the presence of cancer stem cells, which are known to contribute to recurrence and resistance. We also discuss the limitations of the Tumor Control Probability (TCP) model in predicting treatment outcomes, emphasizing that achieving near-total eradication of cancer cells is necessary to prevent recurrence. Our commentary underscores the need for comprehensive research to address these challenges and ensure the efficacy and safety of novel cancer treatments utilizing aminocyanine molecules and NIR light.